Ipsen

IPN

FR0010259150

Pharmaceuticals

Real-time Euronext Paris Other stock markets 09:44:07 2024-04-24 am EDT			5-day change	1st Jan Change
115.5 ^EUR	+3.68%		+8.46%	+6.95%

08:57am	Ipsen: sales up 11% in Q1	CF
Apr. 22	Ipsen Teams Up with Skyhawk Therapeutics on Study of RNA Modulator for Rare Neurological Diseases	MT

Ipsen S.A. Raises Sales Guidance for the Fiscal Year 2021

July 29, 2021 at 01:00 am EDT

Ipsen S.A. raised sales guidance for the fiscal year 2021. For the year, the company expects Total sales growth to be greater than +8.0% (prior guidance: greater than +4.0%).

Latest news about Ipsen

Ipsen: sales up 11% in Q1	02:57am	CF
Ipsen Teams Up with Skyhawk Therapeutics on Study of RNA Modulator for Rare Neurological Diseases	Apr. 22	MT
Ipsen: collaboration agreement with Skyhawk	Apr. 22	CF
Ipsen and Skyhawk Therapeutics Announces RNA Targeting Research Collaboration in Rare Neurological Diseases	Apr. 22	CI
Ipsen: Parvus AM Europe Ltd exceeds 5% of voting rights	Apr. 15	CF
Ipsen: worldwide licensing agreement with Sutro Biopharma	Apr. 02	CF
Ipsen Signs Licensing Deal for Cancer-targeting Antibody Conjugate with Sutro Biopharma	Apr. 02	MT
Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan	Mar. 27	MT
IPSEN : Ipsen’s underlying fundamentals remain promising	Mar. 13
Deutsche Bank Reduces Ipsen PT, Keeps Hold Rating	Feb. 16	MT
IPSEN : Deutsche Bank cuts its target	Feb. 16	CF
IPSEN : UBS reiterates its buy recommendation	Feb. 14	CF
Merrimack Pharmaceuticals to Receive $225 Million Milestone Payment From Ipsen	Feb. 14	MT
Ipsen: new indication approved in pancreatic cancer	Feb. 14	CF
US FDA OKs Ipsen's Metastatic Pancreatic Adenocarcinoma Treatment Regimen in Adults	Feb. 13	MT
Merrimack Pharmaceuticals to Get $225 Million Milestone Payment After FDA's Supplemental NDA Approval	Feb. 13	DJ
Ipsen?s Onivyde Regimen, Potential New Standard-Of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA	Feb. 13	CI
Ipsen S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 08	CI
IPSEN : In line Q4 sales; lower-than-expected 2024 guidance	Feb. 08
Transcript : Ipsen S.A., 2023 Earnings Call, Feb 08, 2024	Feb. 08
Ipsen: 13% drop in annual EPS	Feb. 08	CF
Transcript : Ipsen S.A., 2023 Pre Recorded Earnings Call, Feb 08, 2024	Feb. 07
Ipsen presents positive data for Cabometyx	Jan. 23	CF
Ipsen Announces Latest Phase III Trial Data Investigating Cabometyx®? in Combination with Immunotherapy to Be Present at ASCO Gu 2024	Jan. 22	CI
IPSEN : Deutsche Bank lowers its target price	Dec. 15	CF

Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (75.2%); - neuroscience (21.1%); - rare diseases (3.7%). At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide. Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).

Sector

Pharmaceuticals

Calendar

07:00am - Q1 2024 Sales and Revenue Call

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

IPSEN : Ipsen’s underlying fundamentals remain promising

March 13, 2024 at 11:50 am EDT

More Strategies

Ratings for Ipsen

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

111.4 EUR

Average target price

124.6 EUR

Spread / Average Target

+11.87%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
IPSEN	+6.95%	9.85B
ELI LILLY AND COMPANY	+27.92%	672B
NOVO NORDISK A/S	+26.90%	570B
JOHNSON & JOHNSON	-4.59%	360B
MERCK & CO., INC.	+16.38%	321B
ABBVIE INC.	+9.39%	300B
ASTRAZENECA PLC	+7.43%	217B
ROCHE HOLDING AG	-9.12%	204B
NOVARTIS AG	+5.83%	199B
PFIZER, INC.	-8.58%	149B

Other Pharmaceuticals

Ipsen

Equities

IPN

FR0010259150

Pharmaceuticals

Ipsen S.A. Raises Sales Guidance for the Fiscal Year 2021

Latest news about Ipsen

Chart Ipsen

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Ipsen

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals